Regeneron and Sanofi released preliminary results from the Phase II portion of an ongoing Phase II/III trial evaluating Kevzara (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with severe and critical respiratory illness caused by COVID-19. Following a review by the Independent Data Monitoring Committee (IDMC) of all available data, the trial will be amended so that only critical patients continue to be enrolled to receive Kevzara 400 mg or placebo. Preliminar...